Open Post

TBC....................................................................

We want to solve immune dysfunction.

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or

target cells correctly. We're progressing first-in-class antigen modulators through the clinic,

developed to treat disease by controlling T cell activation. Our technology modulates antigen

presentation, flicking a switch inside cells to alter their appearance to the immune system.

This approach marks a fundamental shift in how we treat people living with autoimmune disorders,

cancers and infectious diseases.

This is a unique opportunity to play a key role during one of the most important phases of the

company's development. You will shape the financial strategy of the organisation, support a planned

IPO, and help build the finance infrastructure required for long-term success as a listed

biotechnology company.